Novo Nordisk CEO Mike Doustdar Talks Drug Sales

Bloomberg Talks - A podcast by Bloomberg

Try Bookbeat 60! days for free, click here

Try Bookbeat 60! days for free, click here

Enjoy a whole world of audiobooks and e-books, everything from new releases to the classics

 Sponsored
Podcast artwork

Categories:

Business

Novo Nordisk has cut its forecast for the fourth time this year, after disappointing sales of its blockbuster drugs Wegovy and Ozempic. It underscores the challenges facing its new chief executive Mike Doustdar. He spoke to Bloomberg's Guy Johnson about the experience so far.   See omnystudio.com/listener for privacy information.

Visit the podcast's native language site